156 related articles for article (PubMed ID: 15477223)
21. A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors.
Conner AC; Hay DL; Simms J; Howitt SG; Schindler M; Smith DM; Wheatley M; Poyner DR
Mol Pharmacol; 2005 Jan; 67(1):20-31. PubMed ID: 15615699
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries.
Gupta S; Lozano-Cuenca J; Villalón CM; de Vries R; Garrelds IM; Avezaat CJ; van Kats JP; Saxena PR; MaassenVanDenBrink A
Naunyn Schmiedebergs Arch Pharmacol; 2007 Mar; 375(1):29-38. PubMed ID: 17295025
[TBL] [Abstract][Full Text] [Related]
23. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature.
Grant AD; Tam CW; Lazar Z; Shih MK; Brain SD
Br J Pharmacol; 2004 Aug; 142(7):1091-8. PubMed ID: 15237099
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of CGRP receptors in the human isolated middle meningeal artery.
Gupta S; Mehrotra S; Avezaat CJ; Villalón CM; Saxena PR; Maassenvandenbrink A
Life Sci; 2006 Jun; 79(3):265-71. PubMed ID: 16458930
[TBL] [Abstract][Full Text] [Related]
25. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
[TBL] [Abstract][Full Text] [Related]
26. The vasorelaxant effect of adrenomedullin, proadrenomedullin N-terminal 20 peptide and amylin in human skin.
Hasbak P; Eskesen K; Lind H; Holst J; Edvinsson L
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):162-7. PubMed ID: 16918718
[TBL] [Abstract][Full Text] [Related]
27. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.
Hay DL; Howitt SG; Conner AC; Schindler M; Smith DM; Poyner DR
Br J Pharmacol; 2003 Oct; 140(3):477-86. PubMed ID: 12970090
[TBL] [Abstract][Full Text] [Related]
28. Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca
Erdling A; Sheykhzade M; Edvinsson L
J Headache Pain; 2017 Dec; 18(1):61. PubMed ID: 28560541
[TBL] [Abstract][Full Text] [Related]
29. Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins (RAMPs) in human brain microvascular and astroglial cells in culture.
Moreno MJ; Terrón JA; Stanimirovic DB; Doods H; Hamel E
Neuropharmacology; 2002 Feb; 42(2):270-80. PubMed ID: 11804624
[TBL] [Abstract][Full Text] [Related]
30. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow.
Tröltzsch M; Denekas T; Messlinger K
Eur J Pharmacol; 2007 May; 562(1-2):103-10. PubMed ID: 17349622
[TBL] [Abstract][Full Text] [Related]
31. Homologous desensitization of calcitonin gene-related peptide-induced relaxation in rat intramural coronary arteries.
Sheykhzade M; Berg Nyborg NC
Eur J Pharmacol; 2004 Jan; 484(1):91-101. PubMed ID: 14729386
[TBL] [Abstract][Full Text] [Related]
32. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation.
Petersen KA; Lassen LH; Birk S; Lesko L; Olesen J
Clin Pharmacol Ther; 2005 Mar; 77(3):202-13. PubMed ID: 15735614
[TBL] [Abstract][Full Text] [Related]
33. The preclinical pharmacology of BIBN4096BS, a CGRP antagonist.
Hay DL; Poyner D
Cardiovasc Drug Rev; 2005; 23(1):31-42. PubMed ID: 15867946
[TBL] [Abstract][Full Text] [Related]
34. CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes.
Sams A; Knyihár-Csillik E; Engberg J; Szok D; Tajti J; Bodi I; Edvinsson L; Vécsei L; Jansen-Olesen I
Eur J Pharmacol; 2000 Nov; 408(2):183-93. PubMed ID: 11080525
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.
Doods H; Hallermayer G; Wu D; Entzeroth M; Rudolf K; Engel W; Eberlein W
Br J Pharmacol; 2000 Feb; 129(3):420-3. PubMed ID: 10711339
[TBL] [Abstract][Full Text] [Related]
36. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist.
Hasbak P; Saetrum Opgaard O; Eskesen K; Schifter S; Arendrup H; Longmore J; Edvinsson L
J Pharmacol Exp Ther; 2003 Jan; 304(1):326-33. PubMed ID: 12490608
[TBL] [Abstract][Full Text] [Related]
37. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity.
Wu D; Doods H; Arndt K; Schindler M
Biochem Soc Trans; 2002 Aug; 30(4):468-73. PubMed ID: 12196117
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of CGRP-induced relaxation in rat intramural coronary arteries.
Sheykhzade M; Berg Nyborg NC
Br J Pharmacol; 2001 Mar; 132(6):1235-46. PubMed ID: 11250874
[TBL] [Abstract][Full Text] [Related]
39. The in vivo effect of adrenomedullin on rat dural and pial arteries.
Juhl L; Petersen KA; Larsen EH; Jansen-Olesen I; Olesen J
Eur J Pharmacol; 2006 May; 538(1-3):101-7. PubMed ID: 16643888
[TBL] [Abstract][Full Text] [Related]
40. The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts.
Chai W; Mehrotra S; Jan Danser AH; Schoemaker RG
Eur J Pharmacol; 2006 Feb; 531(1-3):246-53. PubMed ID: 16438955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
